Nonmyeloablative Conditioning for Mismatched Hematopoietic Stem Cell Transplantation for Severe Sickle Cell Disease

NCT02678143 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped Closed early due to competing studies

Conditions

Sickle Cell Disease

Interventions

DRUG: Alemtuzumab
DRUG: Cyclophosphamide
DRUG: Mycophenolate mofetil
DRUG: Sirolimus
DRUG: Fludarabine
RADIATION: Total body irradiation
PROCEDURE: Hematopoietic stem cell transplant

Sponsor

Washington University School of Medicine